GPTHEALTH

GPT Healthcare Share Price

 

 

Invest in GPT Healthcare with 2.54X leverage

Invest with MTF

Performance

  • Low
  • ₹125
  • High
  • ₹128
  • 52 Week Low
  • ₹123
  • 52 Week High
  • ₹185
  • Open Price₹127
  • Previous Close₹127
  • Volume65,429
  • 50 DMA₹133.25
  • 100 DMA₹138.62
  • 200 DMA₹145.46

Investment Returns

  • Over 1 Month -3.57%
  • Over 3 Month -13.22%
  • Over 6 Month -20.8%
  • Over 1 Year -10.38%

Smart Investing Starts Here Start SIP with GPT Healthcare for Steady Growth!

Invest Now

GPT Healthcare Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 25.3
  • PEG Ratio
  • -1.4
  • Market Cap Cr
  • 1,025
  • P/B Ratio
  • 4
  • Average True Range
  • 3.97
  • EPS
  • 4.94
  • Dividend Yield
  • 2
  • MACD Signal
  • -1.8
  • RSI
  • 37.33
  • MFI
  • 66.54

GPT Healthcare Financials

GPT Healthcare Technicals

EMA & SMA

Current Price
₹124.87
-2.21 (-1.74%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹129.39
  • 50 Day
  • ₹133.25
  • 100 Day
  • ₹138.62
  • 200 Day
  • ₹145.46

Resistance and Support

127.27 Pivot Speed
  • R3 130.99
  • R2 129.81
  • R1 128.45
  • S1 125.91
  • S2 124.73
  • S3 123.37

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

GPT Healthcare Ltd. operates a chain of multi-specialty hospitals under the "ILS Hospitals" brand, offering comprehensive medical services across various specialties. The company provides high-quality healthcare solutions in India, focusing on patient care, innovation, and advanced medical technology.

Gpt Healthcare Ltd has an operating revenue of Rs. 447.58 Cr. on a trailing 12-month basis. An annual revenue growth of 2% is not great, Pre-tax margin of 17% is great, ROE of 20% is exceptional. The company has a reasonable debt to equity of 2%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 16 which is a POOR score indicating inconsistency in earnings, a RS Rating of 41 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 94 indicates it belongs to a poor industry group of Medical-Hospitals and a Master Score of D is close to being the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

GPT Healthcare Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-02 Quarterly Results
2025-11-08 Quarterly Results & Interim Dividend
2025-08-06 Quarterly Results
2025-05-23 Audited Results & Final Dividend
2025-02-11 Quarterly Results
Date Purpose Remarks
2025-11-14 INTERIM Rs.1.00 per share(10%)Interim Dividend
2025-07-29 FINAL Rs.1.50 per share(15%)Final Dividend
2024-11-28 INTERIM Rs.1.00 per share(10%)First Interim Dividend
2024-04-02 INTERIM Rs.1.00 per share(10%)Interim Dividend
View GPT Healthcare Dividend History Arrow

GPT Healthcare F&O

GPT Healthcare Shareholding Pattern

65.57%
4.72%
0.01%
2.73%
19.11%
7.86%

About GPT Healthcare

  • NSE Symbol
  • GPTHEALTH
  • BSE Symbol
  • 544131
  • Managing Director
  • Dr. Om Tantia
  • ISIN
  • INE486R01017

Similar Stocks to GPT Healthcare

GPT Healthcare FAQs

GPT Healthcare share price is ₹124 As on 23 February, 2026 | 14:27

The Market Cap of GPT Healthcare is ₹1024.6 Cr As on 23 February, 2026 | 14:27

The P/E ratio of GPT Healthcare is 25.3 As on 23 February, 2026 | 14:27

The PB ratio of GPT Healthcare is 4 As on 23 February, 2026 | 14:27

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23